Fatal disseminated Acanthamoeba infection in a liver transplant recipient immunocompromised by combination therapies for graft-versus-host disease

Transplant Infectious Disease

Volumn 12, Issue 6, 2010, Pages 529-537

  Young, A L ^a   LeBoeuf, N R ^a   Tsiouris, S J ^a   Husain, S ^a   Grossman, M E ^a  

^a Department of Medicine   (United States)

Author keywords

Acanthamoeba; Immunocompromised; Liver transplant

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; METHYLPREDNISOLONE; MILTEFOSINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE; VIRUS DNA; VORICONAZOLE;

ACANTHAMOEBA; ACANTHAMOEBA INFECTION; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; EPSTEIN BARR VIRUS INFECTION; FECES CULTURE; FRONTAL LOBE; GASTROINTESTINAL BIOPSY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; LEUKOPENIA; LIVER GRAFT; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MALE; MENTAL HEALTH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTOZOON; RASH; SKIN BIOPSY; TREATMENT DURATION;

ACANTHAMOEBA; AMEBIASIS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FATAL OUTCOME; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SKIN DISEASES, PARASITIC;

EID: 78650083587     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00535.x     Document Type: Article

References (40)

1. Grossman ME, Roth J. Cutaneous Manifestations of Infection in the Immunocompromised Host. Baltimore: Williams & Wilkins, 1995.
2. Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003; 16 (2): 273-307.
3. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006; 135 (3): 382-385.
4. Walia R, Montoya JG, Visvesvera GS, Booton GC, Doyle RL. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis 2007; 9 (1): 51-54.
5. Oliva S, Jantz M, Tiernan R, Cook DL, Judson MA. Successful treatment of widely disseminated acanthamoebiasis. South Med J 1999; 92 (1): 55-57.
6. Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis 2008; 14 (11): 1743-1746.
7. Kaul DR, Lowe L, Visvesvara GS, Farmen S, Khaled YA, Yanik GA. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. Transpl Infect Dis 2008; 10 (6): 437-441.
8. Mutreja D, Jalpota Y, Madan R, Tewari V. Disseminated acanthamoeba infection in a renal transplant recipient: a case report. Indian J Pathol Microbiol 2007; 50 (2): 346-348.
9. Barete S, Combes A, De Jonckheere JF, et al. Fatal disseminated Acanthamoeba lenticulata infection in a heart transplant patient. Emerg Infect Dis 2007; 13 (5): 736-738.
10. Readinger A, Blumberg M, Colome-Grimmer MI, Kelly E. Disseminated Acanthamoeba infection with sporotrichoid nodules. Int J Dermatol 2006; 45 (8): 942-943.
11. Duarte AG, Sattar F, Granwehr B, Aronson JF, Wang Z, Lick S. Disseminated acanthamoebiasis after lung transplantation. J Heart Lung Transplant 2006; 25 (2): 237-240.
12. Paltiel M, Powell E, Lynch J, Baranowski B, Martins C. Disseminated cutaneous acanthamebiasis: a case report and review of the literature. Cutis 2004; 73 (4): 241-248.
13. Carter WW, Gompf SG, Toney JF, Greene JN, Cutolo EP. Disseminated Acanthamoeba sinusitis in a patient with AIDS: a possible role for early antiretroviral therapy. AIDS Read 2004; 14 (1): 41-49.
14. Schwarzwald H, Shah P, Hicks J, Levy M, Wagner ML, Kline MW. Disseminated Acanthamoeba infection in a human immunodeficiency virus-infected infant. Pediatr Infect Dis J 2003; 22 (2): 197-199.
15. Steinberg JP, Galindo RL, Kraus ES, Ghanem KG. Disseminated acanthamebiasis in a renal transplant recipient with osteomyelitis and cutaneous lesions: case report and literature review. Clin Infect Dis 2002; 35 (5): e43-e49.
16. Rosenberg AS, Morgan MB. Disseminated acanthamoebiasis presenting as lobular panniculitis with necrotizing vasculitis in a patient with AIDS. J Cutan Pathol 2001; 28 (6): 307-313.
17. Casper T, Basset D, Leclercq C, Fabre J, Peyron-Raison N, Reynes J. Disseminated acanthamoeba infection in a patient with AIDS: response to 5-fluorocytosine therapy. Clin Infect Dis 1999; 29 (4): 944-945.
18. Selby DM, Chandra RS, Rakusan TA, Loechelt B, Markle BM, Visvesvara GS. Amebic osteomyelitis in a child with acquired immunodeficiency syndrome: a case report. Pediatr Pathol Lab Med 1998; 18 (1): 89-95.
19. Murakawa GJ, McCalmont T, Altman J, et al. Disseminated acanthamebiasis in patients with AIDS. A report of five cases and a review of the literature. Arch Dermatol 1995; 131 (11): 1291-1296.
20. Sison JP, Kemper CA, Loveless M, McShane D, Visvesvara GS, Deresinski SC. Disseminated acanthamoeba infection in patients with AIDS: case reports and review. Clin Infect Dis 1995; 20 (5): 1207-1216.
21. Santosh V, Shankar SK, Das S, et al. Pathological lesions in HIV positive patients. Indian J Med Res 1995; 101: 134-141.
22. Anderlini P, Przepiorka D, Luna M, et al. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant 1994; 14 (3): 459-461.
23. Slater CA, Sickel JZ, Visvesvara GS, Pabico RC, Gaspari AA. Brief report: successful treatment of disseminated acanthamoeba infection in an immunocompromised patient. N Engl J Med 1994; 331 (2): 85-87.
24. Martinez AJ. Acanthamoebiasis and immunosuppression. Case report. J Neuropathol Exp Neurol 1982; 41 (5): 548-557.
25. Deluol AM, Teilhac MF, Poirot JL, et al. Cutaneous lesions due to Acanthamoeba sp in a patient with AIDS. J Eukaryot Microbiol 1996; 43 (5): 130S-131S.
26. Helton J, Loveless M, White Jr CR. Cutaneous acanthamoeba infection associated with leukocytoclastic vasculitis in an AIDS patient. Am J Dermatopathol 1993; 15 (2): 146-149.
27. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14 (4): 520-535.
28. Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat Rev 2009; 35 (8): 653-661.
29. Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009; 50 (3): 357-365.
30. Meersseman W, Lagrou K, Sciot R, et al. Rapidly fatal Acanthamoeba encephalitis and treatment of cryoglobulinemia. Emerg Infect Dis 2007; 13 (3): 469-471.
31. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50 (5): 1495-1502.
32. Perales MA, Ishill N, Lomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007; 40 (5): 481-486.
33. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144 (6): 818-831.
34. Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008; 49 (12): 2256-2262.
35. Gonzalez MM, Gould E, Dickinson G, et al. Acquired immunodeficiency syndrome associated with Acanthamoeba infection and other opportunistic organisms. Arch Pathol Lab Med 1986; 110 (8): 749-751.
36. Rivera MA, Padhya TA. Acanthamoeba: a rare primary cause of rhinosinusitis. Laryngoscope 2002; 112 (7, Part 1): 1201-1203.
37. Friedland LR, Raphael SA, Deutsch ES, et al. Disseminated Acanthamoeba infection in a child with symptomatic human immunodeficiency virus infection. Pediatr Infect Dis J 1992; 11 (5): 404-407.
38. Chandrasekar PH, Nandi PS, Fairfax MR, Crane LR. Cutaneous infections due to Acanthamoeba in patients with acquired immunodeficiency syndrome. Arch Intern Med 1997; 157 (5): 569-572.
39. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 2006; 53 (2): 121-126.
40. Ho VT, Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 2008; 21 (2): 223-237.